Solving a 50 year mystery of a missing OPA1 mutation: More insights from the first family diagnosed with autosomal dominant optic atrophy

Molecular Genetics Laboratory, Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tuebingen, Germany. .
Molecular Neurodegeneration (Impact Factor: 6.56). 06/2010; 5(1):25. DOI: 10.1186/1750-1326-5-25
Source: PubMed


Up to the 1950s, there was an ongoing debate about the diversity of hereditary optic neuropathies, in particular as to whether all inherited optic atrophies can be ascribed to Leber's hereditary optic neuropathy (LHON) or represent different disease entities. In 1954 W. Jaeger published a detailed clinical and genealogical investigation of a large family with explicit autosomal dominant segregation of optic atrophy thus proving the existence of a discrete disease different from LHON, which is nowadays known as autosomal dominant optic atrophy (ADOA). Since the year 2000 ADOA is associated with genomic mutations in the OPA1 gene, which codes for a protein that is imported into mitochondria where it is required for mitochondrial fusion. Interestingly enough, the underlying mutation in this family has not been identified since then.
We have reinvestigated this family with the aim to identify the mutation and to further clarify the underlying pathomechanism. Patients showed a classical non-syndromic ADOA. The long term deterioration in vision in the two teenagers examined 50 years later is of particular note 5/20 to 6/120. Multiplex ligation probe amplification revealed a duplication of the OPA1 exons 7-9 which was confirmed by long distance PCR and cDNA analysis, resulting in an in-frame duplication of 102 amino acids. Segregation was verified in 53 available members of the updated pedigree and a penetrance of 88% was calculated. Fibroblast cultures from skin biopsies were established to assess the mitochondrial network integrity and to qualitatively and quantitatively study the consequences of the mutation on transcript and protein level. Fibroblast cultures demonstrated a fragmented mitochondrial network. Processing of the OPA1 protein was altered. There was no correlation of the OPA1 transcript levels and the OPA1 protein levels in the fibroblasts. Intriguingly an overall decrease of mitochondrial proteins was observed in patients' fibroblasts, while the OPA1 transcript levels were elevated.
The thorough study of this family provides a detailed clinical picture accompanied by a molecular investigation of patients' fibroblasts. Our data show a classic OPA1-associated non-syndromic ADOA segregating in this family. Cell biological findings suggest that OPA1 is regulated by post-translational mechanisms and we would like to hypothesize that loss of OPA1 function might lead to impaired mitochondrial quality control. With the clinical, genetic and cell biological characterisation of a family described already more than 50 years ago, we span more than half a century of research in optic neuropathies.

Download full-text


Available from: Nico Fuhrmann,
  • Source
    • "The clinical presentation of DOA is heterogeneous. The ocular phenotype is variable and not all family-members that carry pathogenic mutations in DOA associated genes present visual impairments [19-21,23-26]. The probability for mutation carriers to develop symptoms during lifetime has been estimated at 88% [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Mitochondrial quality control is fundamental to all neurodegenerative diseases, including the most prominent ones, Alzheimer's Disease and Parkinsonism. It is accomplished by mitochondrial network dynamics -- continuous fission and fusion of mitochondria. Mitochondrial fission is facilitated by DRP1, while MFN1 and MFN2 on the mitochondrial outer membrane and OPA1 on the mitochondrial inner membrane are essential for mitochondrial fusion. Mitochondrial network dynamics are regulated in highly sophisticated ways by various different posttranslational modifications, such as phosphorylation, ubiquitination, and proteolytic processing of their key-proteins. By this, mitochondria process a wide range of different intracellular and extracellular parameters in order to adapt mitochondrial function to actual energetic and metabolic demands of the host cell, attenuate mitochondrial damage, recycle dysfunctional mitochondria via the mitochondrial autophagy pathway, or arrange for the recycling of the complete host cell by apoptosis. Most of the genes coding for proteins involved in this process have been associated with neurodegenerative diseases. Mutations in one of these genes are associated with a neurodegenerative disease that originally was described to affect retinal ganglion cells. Since more and more evidence shows that other cell types are affected as well, we would like to discuss the pathology of dominant optic atrophy, which is caused by heterozygous sequence variants in OPA1, in the light of the current view on OPA1 protein function in mitochondrial quality control, in particular on its function in mitochondrial fusion and cytochrome C release. We think OPA1 is a good example to understand the molecular basis for mitochondrial network dynamics.
    Molecular Neurodegeneration 09/2013; 8(1):32. DOI:10.1186/1750-1326-8-32 · 6.56 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic eye diseases (GEDs) are clinically and genetically heterogeneous. Results from molecular genetic testing are redefining the etiology and clinical spectrum of these heritable diseases, helping to explain the observed overlap in clinical phenotypes. Patients and parents benefit from DNA analysis when results confirm a diagnosis or make a diagnosis more specific. Accurate counseling can then be provided regarding the prognosis, presymptomatic diagnosis, life and family-planning issues and whether to anticipate other ocular or systemic medical problems. Patients hope that mutation identification will enable their participation in future clinical trials for treatment. Requests for molecular testing are increasing while those in the visually impaired world and the healthcare professionals who manage them wait to learn long-term results of the first human clinical trials for a GED to be treated with gene therapy, RPE65-type Leber congenital amaurosis. The advantages and disadvantages of molecular testing for ocular diseases are discussed in general, followed by specific details for over 40 GEDs. Some cases are presented to demonstrate testing issues.
    Expert Review of Ophthalmology 03/2011; 6(2):221-245. DOI:10.1586/eop.11.2
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dominant optic atrophy (DOA) and Charcot-Marie-Tooth type 2A disease (CMT2A) are inherited neurological disorders primarily affecting retinal ganglion cells and peripheral nerves, and secondarily, other neuronal cells with high energetic requirements. The discovery of OPA1 mutations in DOA patients and MFN2 ­mutations in CMT2A patients, has defined a new subset of mitochondrial diseases related to mitochondrial dynamics. OPA1 and MFN2 are both dynamin GTPases that promote the fusion of the mitochondrial network. Since diseases related to OPA1 and MFN2 mutations show some clinical similarities, their pathophysiological mechanisms are believed to share some common mitochondrial dysfunctions. These mechanisms are closely ­interdependent and involve mitochondrial fusion, motility along the axons, energy ­production and metabolism, maintenance of the organelle and its genome, as well as ­susceptibility to apoptosis. This chapter presents recent findings on: (1) the clinical diversity of OPA1- and MFN2-related diseases; (2) the spectrum of mutations in the OPA1 and MFN2 genes and their consequences at the protein level; and (3) the pathophysiology of DOA and CMT2A as characterized in cellular and mouse models. Finally, we discuss the therapeutic perspectives opened up by the current knowledge of these diseases. KeywordsDominant optic atrophy-Charcot-Marie-Tooth disease-Mitochondria-MFN2-OPA1
    05/2011: pages 169-196;
Show more